Wednesday, November 06, 2019 3:52:59 PM
“Not necessarily. I think it's kind of business as usual there. But I think we all know that in any acquisition that there's going to be some efficiencies that you try and capture in it, some people that are changing. And so if you look at the 2 large players in the market right now, both of them are undergoing or will be undergoing sort of meaningful changes in the way that those organizations are structured. And as the aesthetics market is very much of a high-touch business, certainly, on the margin, it gives us an opportunity as a single product to really focus well and serve the customer needs.”
My wife is a dermatologist and from discussions with her and her partners the RVNC drug reps can make or break the business model. I have asked her why they always stick with Allergan’s botox and the answer is always the same. They love the Allergan drug reps because they are very easy to deal with. As an example, their dealings with the Dysport reps have always been awful and therefore they don’t use it.
I’m encouraged to see that Foley understands that it is a very “high touch business” when dealing with Dermatologists or Plastic Surgeons, etc.
Isiah Enterprises Activates Scalable Materials Platform Targeting $900B+ Global Market Opportunity; Initiates Strategic Partner Alignment Phase • OWPC • Mar 25, 2026 9:07 AM
ECGI Signs Definitive $25 Million Agreement to Acquire RezyFi • ECGI • Mar 24, 2026 8:30 AM
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • BLOZF • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
